In the course of this dramatic pandemic, the role and significance of sex-and gender-based medicine has, in our opinion, become clear to all. Because the severity and death rate are higher in men than in women.
Covid-19 interacts with another pandemic: non-communicable diseases, in fact, the subjects affected by these diseases such as diabetes are those who have the most serious and lethal forms of Covid-19.
Non-communicable diseases aggregate with each other (for example diabetes mellitus and hypertension) and strongly depend on socio-economic inequalities indicating that Covid-19 is a syndemla. Therefore, it requires a very complex approach that goes beyond the concept of treating the disease to get to take care of people.
Governments of G20, therefore, should stop considering disease only as a purely biological fact because it also depends on social determinants (economic status, education, loneliness, religion, geographical location) because only by integrating and aggregating the social determinants of health and biological facts it is possible to plan how to reduce and mitigate disparities in health.
There is a newly born dimension of medicine: sex-based and gender-based medicine better known as gender medicine that considers both biomedicine-derived and personal care.
Therefore, G20 member states should implement gender medicine through a globally funded global plan to ensure the health of the individual and the population because health is affected by factors that reside outside the health systems.
|Flavia Franconi||W20 Coordinator Equity in Health Commission|
|Florana Menendez||W20 Facilitator Equity in Health Commission and Presidente FEMTEC|
|Agabio Roberta||Department of Biomedical Sciences, Section of Neurosciences and Clinical Pharmacology, University of Cagliari, Italy|
|Campesi Ilaria||PhD in Gender Pharmacology from the University of Sassari|
|Carè Alessandra||Director of Center for Gender-specific medicine. Italian National Institute of Health|
|Carrero Juan-Jesus||PhD Med, PhD Pharm, MBA. Professor of Kidney Epidemiology. Karolinska Institutet|
|Dell’Osso Liliana||Department of Clinical and Experimental Medicine, University of Pisa|
|Glezerman Marek||Tel Aviv University and Rabin Medical Center|
|Kautzky-Willer Alexandra||Medical University of Vienna, Austria|
|Klein Sabra||Ph.D. Professor, Department of Molecular Microbiology and Immunology, Co-director|
|Maguire Peggy||Director General, European Institute of Women's Health,clg|
|Mantovani Alberto||Scientific Director, Istituto Clinico Humanitas, Emeritus Professor, Humanitas University|
|Mercuro Giuseppe||Full professor of Cardiology, Dep of Clinical Sciences and Public Health, University of Cagliari, Sardinia, Italy|
|Raparelli Valeria||MD, PhD, Assistant Professor of Internal Medicine (RTDb), Department of Translational Medicine, Ferrara, Italy|
|Regitz-Zagrosek Vera||Gender in Medicine, Charité, Berlin, Universität Zürich|
|Schiebinger Londa||Stanford University|
|Tannenbaum Cara||MD, Scientific Director, Institute of Gender and Health, Canadian Institutes of Health Research, Canada|
|Wainer Zoe||Director of Clinical Governance, Bupa ANZ. Chair of the Board of Dental Health Services Victoria|
|Klinge Ineke||Associate professor of Gender Medicine at Maastricht University|